CD274 and non-small cell lung carcinoma: Furthermore, O’Brian et al. [14] performed an interim analysis of a randomized phase-III trial (KEYNOTE-091) and found that pembrolizumab significantly improved DFS compared with placebo and was not associated with new safety signals in completely resected, PD-L1-unselected, stage IB to IIIA NSCLC.